Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's potential use in the treatment of Alzheimer's Disease.
Tiziana is the exclusive owner of the world-wide rights for the nasal anti-CD3 for Alzheimer's, MS as well as a number of other neurological diseases .... ''this has a wide potential and it's all been licensed by Tiziana'', he says.
''We're going to look for fast-track designation or encouragement from the FDA because there are no treatments for Alzheimer's Disease ... so we're hoping the FDA will allow us to move this forward as quickly as possible.
''I presented to Tiziana the nasal delivery of Foralumab which they liked very much, we've been working on it, developing it, we actually now have carried on a Phase I trial in healthy volunteers - it's safe, we know the right doses so it's ready to move forward into clinical development.''
